DAWN Day One Biopharmaceuticals
- 17.570
- -0.120-0.68%
- 17.290
- -0.280-1.59%
Day One Biopharmaceuticals News
Day One Biopharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
Day One Biopharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
Day One Biopharmaceuticals | 8-K: Current report
Day One Biopharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Blackman Samuel C.
Day One Biopharmaceuticals | DEFA14A: Others
Day One Biopharmaceuticals | ARS: Annual Report to Security Holders
Day One Biopharmaceuticals | DEF 14A: Definitive information statements
Day One Biopharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Blackman Samuel C.
Day One Biopharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Blackman Samuel C.
Day One Biopharmaceuticals | 8-K: Current report
Day One Biopharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Blackman Samuel C.
Day One Biopharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
Day One Biopharmaceuticals | 10-K: Annual report
Day One Biopharmaceuticals | 8-K: Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
Day One Biopharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Dubow Adam
Day One Biopharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer York Charles N II
Day One Biopharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Blackman Samuel C.
Day One Biopharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Bender Jeremy
Day One Biopharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144
Day One Biopharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-RA Capital Management, L.P.(9.0%),Peter Kolchinsky(9.0%), etc.
Analysis
Price Target
No Data
